Evidence map›Paper›PMID 31618651›Full record

ArticleImmunity2019

Public Endowment of B Cells.

Lars Hangartner

Abstract readComment
In one paragraph

Article in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Lars HangartnerThe Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. Electronic address: lhangart@scripps.edu.

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Dissecting Polyclonal Sera to Reveal Correlates of Productive Immune Responses to HIVR01AI136621 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Lars Oliver Hangartner, Andrew Barrett Ward · 2018 to 2026
$8.0M
NIAID NIH HHS R01 AI136621NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Using a transgenic mouse strain expressing the human V

Indexed as

Financial ManagementOrthomyxoviridaeVaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesGerm CellsHemagglutinin Glycoproteins, Influenza VirusHumansMiceAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusVaccines

Identifiers

PMID31618651
PMCPMC7213522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.